Technical Data
G8950-15F
Granulocyte Colony Stimulating Factor, Recombinant, Human (G-CSF, GCSF, C17orf33, Colony Stimulating Factor 3 (Granulocyte), CSF3, CSF3OS, Filgrastim, Lenograstim, MGC45931, Pluripoietin)
10ug
Growth Factors, Cytokines Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 175aa of human Granulocyte-Colony Stimulating Factor expressed in E.coli is a single,non-glycosylated, polypeptide chain.

Molecular Weight:
~18.8kD

Biological Activity:
The ED50, calculated by the dose-dependent proliferation of mouse NFS-60 indicator cells (measured by 3H-thymidine uptake) is less then 0.1ng/ml, corresponding to a Specific Activity of 1x108 IU/mg.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods: 1.UV spectroscopy at 280nm using the absorbency value of 0.815 as the extinctioncoefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of Recombinant corresponding to G-CSF as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~18.8kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: Not determined
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Granulocyte colony-stimulating factor therapy and systemic inflammation: effect on interleukin-10. Inflamm Res 2005 Sep;54(9):357. 2. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005 Nov 1;23(31):7974-84. 3. [Ureteral cancer producing granulocyte colony-stimulating factor: a case report]. Hinyokika Kiyo 2005 Sep;51(9):627-30. 4. Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor. Exp Hematol 2005 Oct;33(10):1109-17. 5. [Neutropenia induced by taxoids and its control with granulocyte colony-stimulating factor]. Invest Clin 2005 Sep;46(3):265-72. 6. [Granulocyte colony-stimulating factor (G-CSF)]. Nippon Rinsho 2005 Aug;63 Suppl 8:48-50.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.